eXoZymes, Inc.

NASDAQ: EXOZ · Healthcare · Biotechnology

PublicHQ Monrovia, NVCIK 0002010788Reports USD

#1050 of 1,394 Healthcare companies by revenue

EA Score

25D

FH 25DQ 21GM —SS 37

v0.1 · 55/100 weight · provisional

↑ Altman-Z, market scale · ↓ disclosure history, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$9.2M

Employees

Market cap

$78.7M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$70.1k$70.1k2024

Net income-$9.2M-$9.2M2025

Operating income-$9.7M-$9.7M2025

Total assets$6.0M$6.0M2025

Liabilities$2.6M$2.6M2025

Equity$3.4M$3.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

eXoZymes, Inc. booked $70.1k in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -13071.0% net margin.

Peers · Healthcare

Rapid Micro Biosystems, Inc.46D LENSAR Inc55C Champions Oncology, Inc.58C BeyondSpring Inc.34D

Key facts

CEOMichael Heltzen

SectorHealthcare

IndustryBiotechnology

HeadquartersMonrovia, NV

ExchangeNASDAQ: EXOZ

Employees31

IPO date2024-11-13

Latest filings

8-K2026-07-01 8-K2026-06-26 8-K2026-06-17 8-K2026-06-08 10-Q2026-05-14 8-K2026-05-07 8-K2026-04-10 8-K2026-03-31

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.